Drug Profile
Research programme: monoclonal antibody-based therapeutics and diagnostics - multimmune
Alternative Names: mi-TUMEXdx; mi-TUMEXim; mi-TUMEXtxLatest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator multimmune
- Class Diagnostic agents; Imaging agents; Monoclonal antibodies
- Mechanism of Action Diagnostic imaging enhancers; HSP70 heat-shock protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer; Solid tumours
Most Recent Events
- 29 Aug 2023 Preclinical development is ongoing in Germany
- 28 Feb 2020 No recent reports of development identified for preclinical development in Colorectal-cancer in Germany (Parenteral)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in Germany